Beam Therapeutics
BEAM
About: Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Employees: 509
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
24% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 66
6.23% more ownership
Funds ownership: 101.54% [Q1] → 107.78% (+6.23%) [Q2]
7% less capital invested
Capital invested by funds: $1.99B [Q1] → $1.84B (-$141M) [Q2]
9% less funds holding
Funds holding: 236 [Q1] → 215 (-21) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
35% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 54
62% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $37.3M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Barclays
Gena Wang
|
$21
|
Equal-Weight
Maintained
|
6 Aug 2025 |
Financial journalist opinion
Based on 6 articles about BEAM published over the past 30 days
